Fortis Healthcare (FORTIS) investor relations material

Executive summary

• Board recommended a dividend of INR 1 per share (10% of face value) for the fourth consecutive year, subject to shareholder approval, reflecting strong fundamentals and earnings trajectory.

• Consolidated revenue for FY26 rose 17.3% year-over-year to INR 9,128 crore, with Q4 FY26 revenue up 17.8% to INR 2,365 crore.

• Operating EBITDA for FY26 increased 31.3% to INR 2,085 crore, with margins improving to 22.8% from 20.4% in FY25.

• Profit after tax for FY26 grew 31.5% to INR 1,064 crore, and Q4 FY26 PAT rose 44.2% year-over-year to INR 271 crore.

• Approved audited standalone and consolidated financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors.

Financial highlights

• FY26 consolidated revenue reached INR 9,128 crore, up 17.3% year-over-year; hospital revenue grew 19.1% to INR 7,773 crore, diagnostics up 8% to INR 1,355 crore.

• Consolidated operating EBITDA rose 31.3% to INR 2,085 crore (margin 22.8% vs 20.4% last year); profit after tax increased 31.5% to INR 1,064 crore.

• Q4 FY26 revenue was INR 2,365 crore, up 17.8% year-over-year; hospital revenue INR 2,023 crore (+19%), diagnostics INR 341 crore (+11.4%).

• Net debt as of March 31, 2026, stood at INR 2,334 crore; net debt/EBITDA at 1.09x (vs 0.93x last year); net debt to equity was 0.23x at year-end.

• Basic and diluted EPS for FY26 were INR 13.80, compared to INR 10.26 in FY25.

Outlook and guidance

• Hospital business expects 15%+ revenue growth and 150 bps EBITDA margin improvement in FY27.

• Diagnostic business targets 23-24% EBITDA margin and double-digit revenue growth, with 70% of growth from volume and 30% from value.

• Hospital EBITDA margin guidance of 25% by FY28 remains intact, with expected annual improvement of 1.5-2%.

• Planned capacity addition of ~1,800 beds from FY27 to FY30, excluding future inorganic growth.

• Employee stock option scheme 2026 approved and options granted post quarter-end.